FHIR IG analytics| Package | de.medizininformatikinitiative.kerndatensatz.molgen |
| Resource Type | Observation |
| Id | Observation-mii-exa-molgen-therapeutische-implikation-1.json |
| FHIR Version | R4 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
English
Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-1
Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0
status: Final
category: Laboratory, Genetics
code: Therapeutic Implication
subject: Maja Julia Van-der-Dussen (official) Female, DoB: 1968-09-19 ( Medical record number (use: usual, ))
effective: 2022-04-07
performer: Practitioner Dr. Daniel Schmidt(official)
derivedFrom: Observation Genetic variant assessment
component
code: Conclusion Text
value: Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen.
component
code: Medication assessed [ID]
value: BRAF Inhibitor
component
code: Medication assessed [ID]
value: EGFR (Epidermal Growth Factor Receptor) inhibitors
component
code: Medication assessed [ID]
value: Mitogen-activated protein kinase (MEK) inhibitors
German
Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-1
Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0
status: Final
category: Laboratory, Genetik
code: Therapeutic Implication
subject: Maja Julia Van-der-Dussen (official) Female, DoB: 1968-09-19 ( Krankenaktennummer (use: usual, ))
effective: 2022-04-07
performer: Practitioner Dr. Daniel Schmidt(official)
derivedFrom: Observation Genetic variant assessment
component
code: Conclusion Text
value: Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen.
component
code: Medication assessed [ID]
value: BRAF Inhibitor
component
code: Medication assessed [ID]
value: EGFR (Epidermal Growth Factor Receptor) inhibitors
component
code: Medication assessed [ID]
value: Mitogen-activated protein kinase (MEK) inhibitors
{
"resourceType": "Observation",
"id": "mii-exa-molgen-therapeutische-implikation-1",
"meta": {
"profile": [
"https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation|2027.0.0-ballot.1",
"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication|3.0.0"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"status": "final",
"category": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/observation-category",
"code": "laboratory",
"display": "Laboratory"
}
]
},
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0074",
"code": "GE"
}
]
}
],
"code": {
"coding": [
{
"system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code": "therapeutic-implication",
"display": "Therapeutic Implication"
}
]
},
"subject": {
"reference": "Patient/mii-exa-molgen-patient"
},
"effectiveDateTime": "2022-04-07",
"performer": [
{
"reference": "Practitioner/mii-exa-molgen-practitioner-lab"
}
],
"derivedFrom": [
{
"reference": "Observation/mii-exa-molgen-variante-1"
}
],
"component": [
{
"code": {
"coding": [
{
"system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code": "conclusion-string"
}
]
},
"valueString": "Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen."
},
{
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "51963-7",
"display": "Medication assessed [ID]"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://www.whocc.no/atc",
"code": "L01EC",
"display": "B-Raf serine-threonine kinase (BRAF) inhibitors"
},
{
"system": "http://snomed.info/sct",
"code": "703645005",
"display": "Product containing B-Raf inhibitor (product)"
}
],
"text": "BRAF Inhibitor"
}
},
{
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "51963-7",
"display": "Medication assessed [ID]"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://www.whocc.no/atc",
"code": "L01FE",
"display": "EGFR (Epidermal Growth Factor Receptor) inhibitors"
}
]
}
},
{
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "51963-7",
"display": "Medication assessed [ID]"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://www.whocc.no/atc",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
]
}
}
]
}